C
Carmelo Rizzari
Researcher at University of Milano-Bicocca
Publications - 189
Citations - 6249
Carmelo Rizzari is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Medicine & Minimal residual disease. The author has an hindex of 37, co-authored 163 publications receiving 4930 citations. Previous affiliations of Carmelo Rizzari include University of Düsseldorf & University of Milan.
Papers
More filters
Journal ArticleDOI
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
Rob Pieters,Stephen P. Hunger,Joachim Boos,Carmelo Rizzari,Lewis B. Silverman,André Baruchel,Nicola Goekbuget,Martin Schrappe,Ching-Hon Pui +8 more
TL;DR: There is an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL and debate on the optimal formulation and dosage of these agents continues.
Journal ArticleDOI
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg,Franco Locatelli,Gerhard Zugmaier,Rupert Handgretinger,Tanya M. Trippett,Carmelo Rizzari,Peter Bader,Maureen M. O'Brien,Benoit Brethon,Deepa Bhojwani,Paul G. Schlegel,Arndt Borkhardt,Susan R. Rheingold,Todd M. Cooper,Christian M. Zwaan,Phillip Barnette,Chiara Messina,Gérard Michel,Steven G. DuBois,Kuolung Hu,Min Zhu,James A. Whitlock,Lia Gore +22 more
TL;DR: This trial, which to the best of the authors' knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL.
Journal ArticleDOI
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
C. Michel Zwaan,Edward A. Kolb,Dirk Reinhardt,Jonas Abrahamsson,Souichi Adachi,Richard Aplenc,Eveline S. J. M. de Bont,Barbara De Moerloose,Michael Dworzak,Brenda Gibson,Henrik Hasle,Guy Leverger,Franco Locatelli,Christine Ragu,Raul C. Ribeiro,Carmelo Rizzari,Jeffrey E. Rubnitz,Owen P. Smith,Lillian Sung,Daisuke Tomizawa,Marry M. van den Heuvel-Eibrink,Ursula Creutzig,Gertjan J.L. Kaspers +22 more
TL;DR: The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.
Journal ArticleDOI
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Franco Locatelli,Michael B. Jordan,Carl E. Allen,Simone Cesaro,Carmelo Rizzari,Anupama Rao,Barbara A. Degar,Timothy P. Garrington,Julián Sevilla,Maria-Caterina Putti,Franca Fagioli,Martina Ahlmann,Jose-Luis Dapena Diaz,Michael J Henry,Fabrizio De Benedetti,Alexei Grom,Geneviève Lapeyre,Philippe Jacqmin,Maria Ballabio,Cristina de Min +19 more
TL;DR: Empalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis and was not associated with any organ toxicity.
Journal ArticleDOI
Ancestry and pharmacogenetics of antileukemic drug toxicity.
Shinji Kishi,Cheng Cheng,Deborah L. French,Deqing Pei,Soma Das,Edwin H. Cook,Nobuko Hijiya,Nobuko Hijiya,Carmelo Rizzari,Gary L. Rosner,Tony N. Frudakis,Ching-Hon Pui,Ching-Hon Pui,William E. Evans,William E. Evans,Mary V. Relling,Mary V. Relling +16 more
TL;DR: The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers, and Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy.